Argyle Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.32M | Sell |
71,227
-735
| -1% | -$42.8K | 1.4% | 21 |
|
|
2025
Q4 | $3.88M | Buy |
71,962
+3,260
| +5% | +$157K | 1.3% | 22 |
|
|
2025
Q3 | $3.1M | Sell |
68,702
-150
| -0.2% | -$7K | 1.07% | 36 |
|
|
2025
Q2 | $3.19M | Buy |
68,852
+105
| +0.2% | +$5.15K | 1.16% | 30 |
|
|
2025
Q1 | $4.19M | Buy |
68,747
+1,380
| +2% | +$80.4K | 1.56% | 17 |
|
|
2024
Q4 | $3.81M | Buy |
67,367
+2,550
| +4% | +$142K | 1.5% | 19 |
|
|
2024
Q3 | $3.35M | Buy |
64,817
+750
| +1% | +$35.2K | 1.34% | 26 |
|
|
2024
Q2 | $2.66M | Sell |
64,067
-1,385
| -2% | -$62K | 1.09% | 32 |
|
|
2024
Q1 | $3.55M | Buy |
65,452
+834
| +1% | +$42.5K | 1.37% | 24 |
|
|
2023
Q4 | $3.32M | Sell |
64,618
-8,150
| -11% | -$428K | 1.37% | 26 |
|
|
2023
Q3 | $4.22M | Buy |
72,768
+4,535
| +7% | +$278K | 1.55% | 22 |
|
|
2023
Q2 | $4.36M | Sell |
68,233
-5,475
| -7% | -$367K | 1.57% | 19 |
|
|
2023
Q1 | $5.11M | Sell |
73,708
-366
| -0.5% | -$25.8K | 1.8% | 12 |
|
|
2022
Q4 | $5.33M | Hold |
74,074
| – | – | 1.83% | 14 |
|
|
2022
Q3 | $5.27M | Sell |
74,074
-50
| -0.1% | -$3.63K | 2.05% | 9 |
|
|
2022
Q2 | $5.71M | Sell |
74,124
-600
| -0.8% | -$45.7K | 2.05% | 9 |
|
|
2022
Q1 | $5.46M | Sell |
74,724
-4,200
| -5% | -$282K | 1.78% | 14 |
|
|
2021
Q4 | $4.92M | Hold |
78,924
| – | – | 1.54% | 19 |
|
|
2021
Q3 | $4.67M | Hold |
78,924
| – | – | 1.55% | 19 |
|
|
2021
Q2 | $5.27M | Hold |
78,924
| – | – | 1.7% | 16 |
|
|
2021
Q1 | $4.98M | Hold |
78,924
| – | – | 1.68% | 17 |
|
|
2020
Q4 | $4.9M | Sell |
78,924
-130
| -0.2% | -$7.99K | 1.82% | 15 |
|
|
2020
Q3 | $4.77M | Sell |
79,054
-800
| -1% | -$48.1K | 1.95% | 10 |
|
|
2020
Q2 | $4.7M | Sell |
79,854
-334
| -0.4% | -$20K | 1.97% | 9 |
|
|
2020
Q1 | $4.47M | Sell |
80,188
-150
| -0.2% | -$9.17K | 2.11% | 10 |
|
|
2019
Q4 | $5.16M | Sell |
80,338
-820
| -1% | -$47K | 1.83% | 10 |
|
|
2019
Q3 | $4.12M | Buy |
81,158
+550
| +0.7% | +$25.8K | 1.56% | 19 |
|
|
2019
Q2 | $3.66M | Buy |
80,608
+250
| +0.3% | +$11.6K | 1.39% | 26 |
|
|
2019
Q1 | $3.83M | Hold |
80,358
| – | – | 1.47% | 24 |
|
|
2018
Q4 | $4.18M | Sell |
80,358
-1,500
| -2% | -$80.6K | 1.77% | 16 |
|
|
2018
Q3 | $5.08M | Hold |
81,858
| – | – | 1.9% | 10 |
|
|
2018
Q2 | $4.53M | Sell |
81,858
-250
| -0.3% | -$13.5K | 1.8% | 11 |
|
|
2018
Q1 | $5.19M | Sell |
82,108
-2,550
| -3% | -$164K | 2.06% | 6 |
|
|
2017
Q4 | $5.19M | Hold |
84,658
| – | – | 1.94% | 9 |
|
|
2017
Q3 | $5.4M | Sell |
84,658
-100
| -0.1% | -$5.84K | 2.12% | 7 |
|
|
2017
Q2 | $4.72M | Sell |
84,758
-550
| -0.6% | -$29.9K | 1.92% | 6 |
|
|
2017
Q1 | $4.64M | Hold |
85,308
| – | – | 1.89% | 11 |
|
|
2016
Q4 | $4.99M | Buy |
85,308
+3,908
| +5% | +$214K | 2.12% | 5 |
|
|
2016
Q3 | $4.39M | Sell |
81,400
-2,735
| -3% | -$176K | 1.9% | 12 |
|
|
2016
Q2 | $6.19M | Sell |
84,135
-6,553
| -7% | -$463K | 2.63% | 1 |
|
|
2016
Q1 | $5.79M | Sell |
90,688
-1,700
| -2% | -$107K | 2.63% | 2 |
|
|
2015
Q4 | $6.36M | Sell |
92,388
-1,697
| -2% | -$112K | 2.93% | 2 |
|
|
2015
Q3 | $5.57M | Sell |
94,085
-2,697
| -3% | -$171K | 2.72% | 1 |
|
|
2015
Q2 | $6.44M | Sell |
96,782
-3,931
| -4% | -$259K | 2.95% | 1 |
|
|
2015
Q1 | $6.5M | Sell |
100,713
-3,200
| -3% | -$200K | 2.91% | 1 |
|
|
2014
Q4 | $6.13M | Sell |
103,913
-925
| -0.9% | -$52.2K | 2.69% | 1 |
|
|
2014
Q3 | $5.37M | Sell |
104,838
-1,800
| -2% | -$89.9K | 2.47% | 4 |
|
|
2014
Q2 | $5.17M | Sell |
106,638
-750
| -0.7% | -$37K | 2.41% | 2 |
|
|
2014
Q1 | $5.58M | Sell |
107,388
-1,800
| -2% | -$95.8K | 2.74% | 2 |
|
|
2013
Q4 | $5.8M | Sell |
109,188
-2,660
| -2% | -$136K | 2.92% | 1 |
|
|
2013
Q3 | $5.18M | Sell |
111,848
-500
| -0.4% | -$21.9K | 2.84% | 1 |
|
|
2013
Q2 | $5.02M | Buy |
+112,348
| New | +$4.88M | 2.88% | 1 |
|
Other funds holding BMY
VCM
VPM
Argyle Capital Management's BMY Position: Q1 2026 in Review
Argyle Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 1% in Q1 2026, selling an estimated $42.8K and leaving 71,227 shares worth $4.32M. The position accounts for 1.4% of the portfolio, ranked #21.
Argyle Capital Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.5M in Q1 2015. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Argyle Capital Management held 71,227 shares of Bristol-Myers Squibb worth $4.32M as of Q1 2026.
- Argyle Capital Management sold 735 Bristol-Myers Squibb shares in Q1 2026, an estimated $42.8K.
- Bristol-Myers Squibb made up 1.4% of Argyle Capital Management's portfolio in Q1 2026, its #21 holding.
- Argyle Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- Argyle Capital Management's Bristol-Myers Squibb position peaked at $6.5M in Q1 2015.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Argyle Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.